Literature DB >> 6543063

The migration of larval Toxocara canis in mice. II. Post-intestinal migration in primary infections.

M N Abo-Shehada, I V Herbert.   

Abstract

Following oral infection of NIH mice with Toxocara canis embryonated eggs the L2 pass the visceral phase of migration during te first week of infection. Larvae reach the liver and lungs and peak in number in these organs 2 and 3 days after infection, respectively. Larvae are then dispersed throughout the body and enter the myotropic--neurotropic phase by the 7th day of infection. Larvae injected directly into the brain are capable of migrating into the viscera and musculature. Considerable pathology occurs due to larval migrations, especially through the liver and lungs, and both acute and chronic disease are recorded. Studies of infections extending over a year show that the number of recoverable larvae declines gradually with periods of stable populations. On Days 3, 4 and 5 after infection, larvae were demonstrable in the faeces of infected mice. Prenatal infection was observed in a third of the offspring of mice infected the same day as conception.

Entities:  

Mesh:

Year:  1984        PMID: 6543063     DOI: 10.1016/0304-4017(84)90066-9

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  13 in total

1.  Larval distribution, migratory pattern and histological effects of Toxocara canis in Rattus norvegicus.

Authors:  Kennesa Klariz R Llanes; Cyrelle M Besana; Vachel Gay V Paller
Journal:  J Parasit Dis       Date:  2019-09-04

2.  Toxocara canis larvae reinfecting BALB/c mice exhibit accelerated speed of migration to the host CNS.

Authors:  Petra Kolbeková; David Větvička; Jan Svoboda; Karl Skírnisson; Markéta Leissová; Martin Syrůček; Helena Marečková; Libuše Kolářová
Journal:  Parasitol Res       Date:  2011-05-03       Impact factor: 2.289

3.  Imaging of Toxocara canis larvae labelled by CFSE in BALB/c mice.

Authors:  Petra Kolbeková; Libuše Kolářová; David Větvička; Martin Syrůček
Journal:  Parasitol Res       Date:  2010-11-20       Impact factor: 2.289

4.  Induction of matrix metalloproteinase-9 in mice during Toxocara canis larvae migration.

Authors:  S C Lai; K M Chen; H C Chen; H H Lee
Journal:  Parasitol Res       Date:  2005-01-06       Impact factor: 2.289

5.  Effect of various doses of infective Toxocara canis and Toxocara cati eggs on the humoral response and distribution of larvae in mice.

Authors:  K Havasiová-Reiterová; O Tomasovicová; P Dubinský
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

6.  Establishment and migration pattern of Toxocara canis larvae in chickens.

Authors:  Kensuke Taira; Anders Permin; Christian M O Kapel
Journal:  Parasitol Res       Date:  2003-06-26       Impact factor: 2.289

7.  Experimental Toxocara cati infection in gerbils and rats.

Authors:  Mohammad Zibaei; Seyed Mahmoud Sadjjadi; Shoji Uga
Journal:  Korean J Parasitol       Date:  2010-12-16       Impact factor: 1.341

8.  The Prevalence of Toxocariasis and Diagnostic Value of Serologic Tests in Asymptomatic Korean Adults.

Authors:  Jin Young Lee; Moon Hee Yang; Jung Hae Hwang; Mira Kang; Jae Won Paeng; Sehyo Yune; Byung Jae Lee; Dong Chull Choi
Journal:  Allergy Asthma Immunol Res       Date:  2015-06-04       Impact factor: 5.764

9.  Neurotoxocarosis: marked preference of Toxocara canis for the cerebrum and T. cati for the cerebellum in the paratenic model host mouse.

Authors:  Elisabeth Janecek; Andreas Beineke; Thomas Schnieder; Christina Strube
Journal:  Parasit Vectors       Date:  2014-04-22       Impact factor: 3.876

10.  ANTHELMINTIC ACTIVITY OF LAPACHOL, β-LAPACHONE AND ITS DERIVATIVES AGAINST Toxocara canis LARVAE.

Authors:  Taís Mata-Santos; Nitza França Pinto; Hilton Antônio Mata-Santos; Kelly Gallan De Moura; Paula Fernandes Carneiro; Tatiane Dos Santos Carvalho; Karina Pena Del Rio; Maria do Carmo Freire Ribeiro Pinto; Lourdes Rodrigues Martins; Juliana Montelli Fenalti; Pedro Eduardo Almeida Da Silva; Carlos James Scaini
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 May-Jun       Impact factor: 2.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.